| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Division of Hematology/Oncology, Department of Medicine and 2 Department of Preventive Medicine, Northwestern University Medical School and the Robert H. Lurie Cancer Center of Northwestern University, Chicago, Illinois; 3 Division of Medical Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas; and 4 Medicine and 5 Chemoprevention Branches, National Cancer Institute, NIH, Bethesda, Maryland
Preclinical studies suggest that the isoflavone genistein may have prostate cancer chemopreventive activity. Genistein has been shown to alter cellular levels of protein-tyrosine phosphorylation and is present at high levels in soy. This study was designed to measure the pharmacokinetic parameters of two different preparations of unconjugated soy isoflavones, PTI G-2535 and PTI G-4660 (which contain 43% and 90% genistein, respectively), in human subjects with cancer, to evaluate toxicity and obtain pilot data on in vivo effects on protein-tyrosine phosphorylation. Cohorts of four patients were given single doses of each preparation; each dose was separated by 1 week. Sequential cohorts received genistein at 2, 4, or 8 mg/kg orally. Pharmacokinetic sampling was performed after each dose, and tyrosine phosphorylation was measured in proteins extracted from peripheral blood mononuclear cells. One of 13 patients treated developed a treatment-related rash. No other toxicities were observed. Maximal plasma concentrations (Cmax) ranged between 4.3 and 16.3 µM for total genistein and 0.066 and 0.17 µM for free genistein. For PTI G-2535 and PTI G-4660, half-life was 15.03 and 22.41 h, respectively, and volume of distribution was 189.9 and 653.8 liters, respectively, and there was a trend toward higher area under the concentration curve for PTI G-2535 (P = 0.07 at the 8 mg/kg dose). Treatment-related increases in tyrosine phosphorylation were observed in peripheral blood mononuclear cells. Oral administration of soy isoflavones gives plasma concentrations of genistein that have been associated with antimetastatic activity in vitro.
This article has been cited by other articles:
|
|
 |
|
  M. Lakshman, L. Xu, V. Ananthanarayanan, J. Cooper, C. H. Takimoto, I. Helenowski, J. C. Pelling, and R. C. Bergan Dietary Genistein Inhibits Metastasis of Human Prostate Cancer in Mice Cancer Res., March 15, 2008; 68(6): 2024 - 2032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Craft, L. Xu, D. Romero, C. P. H. Vary, and R. C. Bergan Genistein Induces Phenotypic Reversion of Endoglin Deficiency in Human Prostate Cancer Cells Mol. Pharmacol., January 1, 2008; 73(1): 235 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. J. Wang, J. Chen, X. Jia, V. H. Tam, and M. Hu Disposition of Flavonoids via Enteric Recycling: Structural Effects and Lack of Correlations between in Vitro and in Situ Metabolic Properties Drug Metab. Dispos., November 1, 2006; 34(11): 1837 - 1848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Xu and R. C. Bergan Genistein Inhibits Matrix Metalloproteinase Type 2 Activation and Prostate Cancer Cell Invasion by Blocking the Transforming Growth Factor beta-Mediated Activation of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2-27-kDa Heat Shock Protein Pathway Mol. Pharmacol., September 1, 2006; 70(3): 869 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Shen, M. H. Liu, T. Y. Ng, Y. H. Chan, and E. L. Yong Differential Effects of Isoflavones, from Astragalus Membranaceus and Pueraria Thomsonii, on the Activation of PPAR{alpha}, PPAR{gamma}, and Adipocyte Differentiation In Vitro J. Nutr., April 1, 2006; 136(4): 899 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cassidy, J. E. Brown, A. Hawdon, M. S. Faughnan, L. J. King, J. Millward, L. Zimmer-Nechemias, B. Wolfe, and K. D.R. Setchell Factors Affecting the Bioavailability of Soy Isoflavones in Humans after Ingestion of Physiologically Relevant Levels from Different Soy Foods J. Nutr., January 1, 2006; 136(1): 45 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chen, S. Wang, X. Jia, S. Bajimaya, H. Lin, V. H. Tam, and M. Hu DISPOSITION OF FLAVONOIDS VIA RECYCLING: COMPARISON OF INTESTINAL VERSUS HEPATIC DISPOSITION Drug Metab. Dispos., December 1, 2005; 33(12): 1777 - 1784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Li, Z. Zhang, D. L. Hill, X. Chen, H. Wang, and R. Zhang Genistein, a Dietary Isoflavone, Down-Regulates the MDM2 Oncogene at Both Transcriptional and Posttranslational Levels Cancer Res., September 15, 2005; 65(18): 8200 - 8208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Uzick Naturopathic Approaches Integr Cancer Ther, September 1, 2005; 4(3): 253 - 258. [PDF]
|
|
|
|
|
|
M. F. Aguero, M. M. Facchinetti, Z. Sheleg, and A. M. Senderowicz Phenoxodiol, a Novel Isoflavone, Induces G1 Arrest by Specific Loss in Cyclin-Dependent Kinase 2 Activity by p53-Independent Induction of p21WAF1/CIP1 Cancer Res., April 15, 2005; 65(8): 3364 - 3373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Vantyghem, S. M. Wilson, C. O. Postenka, W. Al-Katib, A. B. Tuck, and A. F. Chambers Dietary Genistein Reduces Metastasis in a Postsurgical Orthotopic Breast Cancer Model Cancer Res., April 15, 2005; 65(8): 3396 - 3403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Huang, S. Chen, L. Xu, Y. Liu, D. K. Deb, L. C. Platanias, and R. C. Bergan Genistein Inhibits p38 Map Kinase Activation, Matrix Metalloproteinase Type 2, and Cell Invasion in Human Prostate Epithelial Cells Cancer Res., April 15, 2005; 65(8): 3470 - 3478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. McCarty Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380. [Abstract] [PDF]
|
|
|
|
 |
|
 R. A. Sharma, S. A. Euden, S. L. Platton, D. N. Cooke, A. Shafayat, H. R. Hewitt, T. H. Marczylo, B. Morgan, D. Hemingway, S. M. Plummer, et al. Phase I Clinical Trial of Oral Curcumin: Biomarkers of Systemic Activity and Compliance Clin. Cancer Res., October 15, 2004; 10(20): 6847 - 6854. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
